Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences ...

Oncternal could receive up to $65 million in milestones if the programs are successful. Regulatory events account for $40 ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the ...

Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Shanghai and San Francisco Bay Area-based HanchorBio has already taken HCB101, an engineered SIRPα-IgG4 Fc fusion protein, into phase 2 trials for solid tumors and hematologic malignancies, including ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...